Position in LLY
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$65,635,213
+$16,929,713 QoQ
Shares Held
54,722
+3.3% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
1.60%
of 13F equity value
Holder Rank
#477
of 4,605 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Callan Family Office, LLC holds $198,735,685 across 16 Drug Manufacturers - General names. LLY ranks #1 (33.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
This page
|
54,722 | $65,635,213 | |
| 2 | NVS |
Novartis AG
|
107,922 | $16,913,535 | |
| 3 | JNJ |
Johnson & Johnson
|
64,905 | $16,483,922 | |
| 4 | ABBV |
AbbVie Inc.
|
58,732 | $14,779,320 | |
| 5 | GSK |
GSK plc
|
271,081 | $14,210,066 | |
| 6 | MRK |
Merck & Co., Inc.
|
107,070 | $13,758,495 | |
| 7 | AZN |
Astrazeneca PLC
|
69,688 | $13,214,238 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
101,450 | $12,817,193 |
All Filings in LLY
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $65,635,213 | 54,722 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $48,705,500 | 52,954 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $58,670,010 | 54,593 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $30,957,199 | 40,573 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $33,371,679 | 42,810 | Shares | Sole | 2025-07-24 | |
| 2025-03-31 | $18,934,812 | 22,926 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $17,373,860 | 22,505 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $675,972 | 763 | Shares | Sole | 2024-10-08 | |
| 2024-06-30 | $529,647 | 585 | Shares | Sole | 2024-07-26 | |
| 2024-03-31 | $226,386 | 291 | Shares | Sole | 2024-05-09 | |
| No filing history on record for this holder in this stock. | ||||||